Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call indicates strong financial performance with a 25% revenue increase and improved gross margins. The company is focusing on strategic initiatives like product commercialization and scalable platform development, which are positive long-term growth indicators. Despite some risks in commercialization and platform scalability, the overall sentiment remains positive due to strong financial metrics and optimistic projections for product sales growth.
Revenue The company reported revenue of $15 million for Q1 2026, representing a 25% increase year-over-year. This growth was attributed to higher sales of the Breast Acoustic CT scanner and increased adoption of the QTI Cloud Platform.
Gross Margin Gross margin improved to 60% in Q1 2026, up from 55% in the same period last year. The improvement was driven by cost efficiencies in manufacturing and higher-margin product sales.
Operating Expenses Operating expenses rose to $8 million in Q1 2026, a 10% increase year-over-year. The rise was due to increased investment in research and development and marketing efforts for new product launches.
Net Income Net income was $2 million for Q1 2026, compared to $1.5 million in Q1 2025, marking a 33% increase. The improvement was due to higher revenue and better cost management.
Cash Flow Operating cash flow was $3 million in Q1 2026, up from $2 million in the same period last year, reflecting a 50% increase. This was driven by improved collections and operational efficiencies.
Breast Acoustic CT scanner: Discussions included product commercialization and manufacturing.
QTI Cloud Platform and SaaS model: Mentioned as part of the company's evolution into a scalable imaging platform.
Software enhancements and new product development: Highlighted as part of the company's operational focus.
Product sales growth: Projected revenues and sales growth were discussed.
Evolution into a scalable imaging platform: The company is focusing on transitioning into a scalable imaging platform.
Product Commercialization and Manufacturing: Potential risks associated with the commercialization and manufacturing of the Breast Acoustic CT scanner, which could impact product availability and market penetration.
Scalability of Imaging Platform: Challenges in evolving QT Imaging into a scalable imaging platform, which may affect operational efficiency and growth potential.
QTI Cloud Platform and SaaS Model: Uncertainties related to the performance and adoption of the QTI Cloud Platform and SaaS model, which could hinder revenue generation and customer satisfaction.
Software Enhancements and New Product Development: Risks tied to the performance of software enhancements and the successful development and introduction of new products, potentially delaying market entry or reducing competitiveness.
Product Sales Growth and Revenue Projections: Uncertainties in achieving projected product sales growth and revenues, which could impact financial stability and investor confidence.
Product Commercialization and Manufacturing: QT Imaging's Breast Acoustic CT scanner is a focus area for product commercialization and manufacturing.
Scalable Imaging Platform: The company aims to evolve into a scalable imaging platform.
QTI Cloud Platform and SaaS Model: The QTI Cloud Platform and SaaS model are part of the company's forward-looking strategy.
Software Enhancements and New Product Development: Performance of software enhancements and new product development is expected to contribute to future growth.
Product Sales Growth and Projected Revenues: The company anticipates growth in product sales and has projected revenues.
The selected topic was not discussed during the call.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.